Related Experiment Video
Updated: Aug 28, 2025

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
MicoRNA-214-3p: a key player in CPLX2-mediated inhibition on temozolomide resistance in glioma
Qian Peng1, Lijiao Wang2, Shuling Wang3
1Medical Department Hunan Provincial People's Hospital, (the First Affiliated Hospital of Hunan Normal University), Changsha P.R. China.
Objective:
This study plans to investigate whether miR-214-3p could bind CPLX2 to regulate temozolomide (TMZ) resistance in glioma.
Methods:
The differential expression of miR-214-3p and CPLX2 was determined by qRT-PCR and Western blotting in TMZ-resistant glioma tissues. Then, TMZ-resistant glioma cells (U87/TMZ and U251/TMZ) were established and transfected with miR-214-3p mimic, miR-214-3p inhibitor, pcDNA3.1-CPLX2 or pcDNA3.1-CPLX2 plus miR-214-3p mimic to evaluate the impact of miR-214-3p and CPLX2 on the proliferation, apoptosis and TMZ resistance in U87/TMZ and U251/TMZ cells. The binding relationship between miR-214-3p and CPLX2 was reported by dual-luciferase reporter assay.
Results:
Higher miR-214-3p and lower CPLX2 expression levels were revealed in TMZ-sensitive glioma tissues. The alterations in miR-214-3p and CPLX2 expression were more significant in TMZ-resistant tissues compared with TMZ-sensitive tissues. In cellular experiments, TMZ-resistant cells expressed higher miR-214-3p expression and lower CPLX2 expression than TMZ-sensitive cells. Transfection of miR-214-3p mimic elevated the proliferation and half maximal inhibitory concentration (IC50) and decreased the apoptosis in U87/TMZ and U251/TMZ cells. Introduction of miR-214-3p inhibitor or pcDNA3.1-CPLX2 reduced the proliferation and IC50 value and prompted the apoptosis in TMZ-resistant glioma cells. The effects of pcDNA3.1-CPLX2 on inhibiting the proliferation and IC50 value and enhancing the apoptosis in TMZ-resistant glioma cells were hindered by the transfection of miR-214-3p mimic. In addition, CPLX2 was a target gene of miR-214-3p.
Conclusion:
Downregulation of miR-214-3p inhibits TMZ resistance in glioma by promoting CPLX2.
Insights
Downregulating miR-214-3p inhibits temozolomide resistance in glioma by increasing CPLX2 expression. This finding offers a potential therapeutic strategy for overcoming drug resistance in brain tumors.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options.
- Temozolomide (TMZ) is a standard chemotherapeutic agent for GBM, but resistance often develops.
- MicroRNAs (miRNAs) play crucial roles in cancer progression and drug resistance.
Purpose of the Study:
- To investigate the role of miR-214-3p in regulating temozolomide (TMZ) resistance in glioma.
- To determine if miR-214-3p targets CPLX2 (C জটিল প্রোটিন 2) and influences TMZ resistance.
Main Methods:
- Quantitative real-time PCR (qRT-PCR) and Western blotting were used to assess miR-214-3p and CPLX2 expression in glioma tissues and cells.
- TMZ-resistant glioma cell lines (U87/TMZ and U251/TMZ) were established and transfected with miR-214-3p mimic, inhibitor, or CPLX2 constructs.
- Cell proliferation, apoptosis, and TMZ sensitivity (IC50) were evaluated.
- Dual-luciferase reporter assays confirmed the binding relationship between miR-214-3p and CPLX2.
Main Results:
- miR-214-3p was upregulated, and CPLX2 was downregulated in TMZ-resistant glioma tissues and cells compared to sensitive ones.
- Overexpression of miR-214-3p increased proliferation and TMZ resistance while decreasing apoptosis in resistant cells.
- Inhibition of miR-214-3p or overexpression of CPLX2 reduced proliferation and TMZ resistance and enhanced apoptosis.
- CPLX2 was confirmed as a direct target of miR-214-3p.
Conclusions:
- miR-214-3p promotes TMZ resistance in glioma by downregulating CPLX2.
- Downregulation of miR-214-3p or upregulation of CPLX2 could be a therapeutic strategy to overcome TMZ resistance in glioma.
More Related Videos
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Related Concept Videos
MicroRNAs
Abnormal Proliferation